Latest News
MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site
Past Events
October 28, 2024 10:00 AM ET18th Annual Pain Therapeutics Summit
You are about to review presentations, reports and/or filings of MIRA Pharmaceuticals, Inc., that contain time-sensitive information. The information contained therein is only accurate as of the date thereof. MIRA Pharmaceuticals, Inc. will not be reviewing or updating the material that is contained in these items after the date thereof. The information contained therein may be updated, amended, supplemented or otherwise altered by subsequent presentations, reports and/or filings by MIRA Pharmaceuticals, Inc.
Latest Presentation
Latest Financial Results
Q2 2024
Quarter Ended Jun 30, 2024
Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Terms of Use.
Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Terms of Use.
Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Terms of Use.
Latest Annual Filing
For Fiscal Year Ending Dec 31, 2023
Email Alerts
& get notified, as they happen
Company Overview
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. MIRA holds the exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a novel, patent-pending oral ketamine analog under investigation to treat neuropathic pain (NP), treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDD-SI), and post-traumatic stress disorder (PTSD).
MIRA’s noval oral pharmaceutical marijuana analog, MIRA-55, is currently under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. If approved by the FDA, MIRA-55 could mark a significant advancement in addressing various neuropsychiatric, inflammatory, and neurologic diseases and disorders.
The U.S. Drug Enforcement Administration’s scientific review concluded that both Ketamir-2 and MIRA-55 would not be considered controlled substances or listed chemicals under the Controlled Substances Act and its governing regulations.
Symbol
NASDAQ: MIRAPrice
$Volume
Change
IR Contacts
Company
MIRA Pharmaceuticals, Inc.
1200 Brickell Ave.
Suite 1950 #1183
Miami, FL 33131
United States
T: 786-432-9792
info@mirapharma.com
Investor Relations
MIRA Pharmaceuticals, Inc.
T: 786-432-9792
info@mirapharma.com
Transfer Agent
Equiniti
48 Wall Street, 23rd FL.
New York, NY 10005
T: US 800-401-1957
Canada/US Virgin Islands 800-468-9716
Other Internationl Access Codes
Rohan.bickram@equiniti.com